Arthneeti
Lasa SupergeneriQ3 FY21

Lasa Supergeneri Q3 FY21 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹6.2Market Cap: ₹33 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4
  • LASA Supergenerics expects a growth rate of around 7% to 10% if market conditions remain stable (Page 7).
  • Focus is on volume growth rather than immediate topline jump, especially through existing products (Page 6).
  • Progesterone (human API) sales are currently small (~Rs. 10 crore included in topline) but expected to pick up gradually (Page 4).
  • Capacity expansion underway: first phase increasing capacity from 4300 to 5300 metric tons by March, second phase planned within next year (Page 9).
  • Exports constitute around 50% (direct ~17%), and the company aims to maintain or slightly increase export share (Page 8).
  • Company emphasizes sustainable EBITDA margins between 20-23% despite competition, aiming to protect profitability amid market uncertainties (Page 11).

See what Lasa Supergeneri management said on margin guidance — free account, 30 seconds.

Fundraise plans

- The company has repaid most of its working capital debt and is currently virtually debt-free. - Remaining debt with Bank of Baroda is under settlement with a verbal nod received for repayment. - No mention of new debt fundraising in the current quarter. - Free cash flow generated will primarily be used for: - Incremental working capital requirements. - Expansion of business (volume growth of existing products). - No discussion or announcement of any current or future equity fundraising. - Management is focused on improving cash flow, return on capital, and utilizing surplus cash for business growth or shareholder rewards (e.g., dividends). - Any additional capacity expansion plans will be internally funded via surplus cash flow. In summary, no explicit plans for new debt or equity fundraising were disclosed; the company prefers leveraging internal accruals to fund growth and working capital needs.

See what Lasa Supergeneri management said on order book — free account, 30 seconds.

Capex plans

Yes
  • LASA Supergenerics is currently undergoing a capital expenditure (CAPEX) primarily focused on expanding capacity and volume growth of existing products.
  • No new products are planned under the current CAPEX; the focus is on volume growth of existing product lines.
  • The first phase of capacity expansion (adding around 1,000 metric tons to existing 4,300 metric tons, totaling 5,300 metric tons) is expected to complete by March 2021.
  • Plans for the second phase of capacity expansion (up to 5,800 metric tons) are under evaluation; timelines will be communicated in due course, expected within the next year.
  • CAPEX done in recent months is yet to be fully capitalized and will reflect once commissioning is complete.
  • Free cash flows generated will be used for working capital and business expansion.
  • The company is debt-free except for a balance under settlement and has reserved funds to clear it.
  • No explicit mention of strategic investments or acquisitions at this time, though Harishree Aromatics scheme is awaiting NCLT approval.

Track Lasa Supergeneri — get its next earnings analysis in your feed

Margin guidance

Category 3
  • LASA Supergenerics expects a steady growth rate of around 7% to 10% going forward, contingent on favorable market conditions.
  • The company emphasizes maintaining healthy EBITDA margins around 20-23%, considering the Chinese competition and raw material costs.
  • EBITDA margins beyond 23-25% are considered unlikely due to competitive pressures.
  • Growth will mainly be driven by volume expansion of existing products rather than addition of new products.
  • The human API segment (specifically Progesterone) is expected to grow gradually but is currently a small part of revenue (~Rs. 10 crore included in current topline).
  • They aim for consistent topline with focus on profitability rather than just sales growth.
  • Cash flows generated will be reinvested for working capital, capacity expansion, and potentially shareholder rewards like dividends.
  • The company is virtually debt-free, supporting financial stability for future growth.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for LASA Supergenerics Limited. However, relevant inferences from the Q&A include: - Exports contribute about 17% directly and around 50% including indirect exports, indicating ongoing orders from international markets. - Competition, especially from China, affects order wins due to their inventory and pricing strategies. - The company strives for consistent topline growth despite market challenges. - The bird flu and COVID-19 vaccine drive may impact demand and government tenders, indicating some uncertainty in order inflow. - Litigation and patent protection efforts are ongoing to protect the company's market share. - Capacity expansions (from 4300 to 5300 MT, with plans for 5800 MT) suggest anticipation of increased order volumes. No specific orderbook value or pending orders were disclosed.

How does Lasa Supergeneri rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisLasa Supergeneri
Rev 4Mar 3
See where Lasa Supergeneri sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Lasa Supergeneri rank in Pharmaceuticals & Biotechnology?

Compare Lasa Supergeneri against every Pharmaceuticals & Biotechnology company (Q3 FY21) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Continue your research

What Lasa Supergeneri's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • IOL Chemicals (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharma. (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

  • Strides Pharma Science Ltd (Q1 FY27)

    markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →